CLAIMS

1. Use of a composition comprising nanoparticles comprising a paclitaxel coated with an albumin in the manufacture of a medicament for treating bladder cancer in an individual in need thereof, wherein the medicament is to be administered intravesicularly.

2. The use according to claim 1, wherein the bladder cancer is non-muscle-invasive bladder cancer.

3. The use according to claim 1 or 2, wherein the bladder cancer is refractory to treatment with BCG, mitomycin C, or interferon.

4. The use according to any one of claims 1-3, wherein the medicament is to be administered at the dose of paclitaxel of about 100 mg to about 600 mg.

5. The use according to claim 4, wherein the medicament is to be administered at the dose of paclitaxel of about 150 mg to about 500 mg.

6. The use according to claim 4 or 5, wherein the medicament is to be administered once weekly.

7. The use according to claim 1 wherein the bladder cancer is platinum-refractory bladder cancer.

8. The use according to claim 7, wherein the platinum-refractory bladder cancer is metastatic bladder cancer.

9. The use according to any one of claims 1-8, wherein the medicament is to be administered in combination with at least one other agent.

10. Use of a composition comprising nanoparticles comprising a paclitaxel coated with an albumin in the manufacture of a medicament for treating bladder cancer in an individual, wherein the medicament is to be administered concurrently with an effective amount of a platinum-based agent and an effective amount of an antimetabolite.

11. The use according to claim 10, wherein the bladder cancer is platinum-refractory bladder cancer.

12. The use according to claim 10 or 11, wherein the cancer is locally advanced bladder cancer.

13. The use according to any one of claims 10-12, wherein the cancer is muscle-invasive bladder cancer.

14. The use according to any one of claims 10-13, wherein the medicament is to be administered intravenously.

15. The use according to claim 14, wherein the medicament is to be administered at about 260-300 mg/m^2 of paclitaxel.

16. The use according to any one of claims 10-15, wherein the platinum-based agent is carboplatin.

17. The use according to any one of claims 10-16, wherein the antimetabolite is gemcitabine.

18. The use according to claim 16, wherein the carboplatin is to be administered intravenously at AUC of about 5.

19. The use according to claim 17, wherein gemcitabine is to be administered intravenously at about 800 mg/m^2.

20. The use according to any one of claims 1-19, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.

21. The use according to claim 20, wherein the nanoparticles in the composition have an average diameter of less than about 200 nm.

22. The use according to any one of claims 1-21, wherein the bladder cancer is urothelial carcinoma.

23. The use according to any one of claims 1-22, wherein the bladder cancer is a high grade bladder cancer.

24. The use according to any one of claims 1-23, wherein the individual is human.

25. The use according to any one of claims 1-24, wherein the albumin is human albumin.

26. The use according to any one of claims 1-24, wherein the albumin is human serum albumin.

27. A kit comprising: a) a composition comprising nanoparticles comprising a paclitaxel coated with an albumin, and b) instructions for administering the nanoparticle composition for treatment of bladder cancer, wherein the composition is to be administered intravesicularly.

28. The kit according to claim 27, wherein the kit comprises an effective amount of one other agent.

29. The kit according to claim 28, wherein the agent inhibits microtubule assembly.

30. The kit according to any one of claims 27-29, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.

31. The kit according to any one of claims 27-30, wherein the albumin is human albumin.

32. The kit according to any one of claims 27-30, wherein the albumin is human serum albumin.

33. A kit comprising: a) a composition comprising nanoparticles comprising a paclitaxel coated with an albumin, b) a platinum-based agent, c) gemcitabine, and d) instructions for administering the nanoparticle composition, the platinum-based agent, and the gemcitabine for treatment of bladder cancer.

34. The kit according to claim 33, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.

35. The kit according to claim 33 or 34, wherein the albumin is human albumin.

36. The kit according to claim 33 or 34, wherein the albumin is human serum albumin.

CLAIMS

1. Use of a composition comprising nanoparticles comprising a taxane and an albumin in the manufacture of a medicament for treating bladder cancer in an individual in need thereof.

2. The use according to claim 1, wherein the bladder cancer is non-muscle-invasive bladder cancer.

3. The use according to claim 1 or 2, wherein the bladder cancer is refractory to treatment with BCG, mitomycin C, or interferon.

4. The use according to any one of claims 1-3, wherein the medicament is to be administered intravesicularly.

5. The use according to claim 4, wherein the medicament is to be administered at the dose of about 100 mg to about 600 mg.

6. The use according to claim 5, wherein the medicament is to be administered at the dose of about 150 mg to about 500 mg.

7. The use according to any one of claims 4-6, wherein the medicament is to be administered once weekly.

8. The use according to claim 1 wherein the bladder cancer is platinum-refractory bladder cancer.

9. The use according to claim 8, wherein the platinum-refractory bladder cancer is metastatic bladder cancer.

10. The use according to claim 8 or 9, wherein the medicament is to be administered intravenously.

11. The use according to claim 10, wherein the medicament is to be administered at the dose of about 150 mg/m^2 to about 350 mg/m^2.

~~12. The use according to claim 11, wherein the medicament is to be administered at the~~ dose of about 260 mg/m^2 to about 300 mg/m^2.

13. The use according to any one of claims 10-12, wherein the medicament is to be administered once every three weeks.

14. The use according to any one of claims 1-13, wherein the medicament is to be administered in combination with at least one other agent.

15. Use of a composition comprising nanoparticles comprising a taxane and albumin in the manufacture of a medicament for treating bladder cancer in an individual, wherein the medicament is to be administered concurrently with an effective amount of a platinum-based agent and an effective amount of an antimetabolite.

16. The use according to claim 15, wherein the bladder cancer is platinum-refractory bladder cancer.

17. The use according to claim 15 or 16, wherein the cancer is locally advanced bladder cancer.

18. The use according to any one of claims 15-17, wherein the cancer is muscle-invasive bladder cancer.

19. The use according to any one of claims 15-18, wherein the medicament is to be administered intravenously.

20. The use according to claim 19, wherein the medicament is to be administered at about 260-300 mg/m^2.

21. The use according to any one of claims 15-20, wherein the platinum-based agent is carboplatin.

22. The use according to any one of claims 15-21, wherein the antimetabolite is gemcitabine.

23. The use according to claim 21, wherein the carboplatin is to be administered intravenously at AUC of about 5.

24. The use according to claim 22, wherein gemcitabine is to be administered intravenously at about 800 mg/m^2.

25. The use according to any one of claims 1-24, wherein the taxane is paclitaxel.

26. The use according to any one of claims 1-25, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.

27. The use according to claim 26, wherein the nanoparticles in the composition have an average diameter of less than about 200 nm.

28. The use according to any one of claims 1-27, wherein the taxane in the nanoparticles are coated with albumin.

29. The use according to any one of claims 1-28, wherein the bladder cancer is urothelial carcinoma.

30. The use according to any one of claims 1-29, wherein the bladder cancer is a high grade bladder cancer.

31. The use according to any one of claims 1-30, wherein the individual is human.

32. The use according to any one of claims 1-31, wherein the albumin is human albumin.

33. The use according to any one of claims 1-31, wherein the albumin is human serum albumin.

34. A kit comprising: a) a composition comprising nanoparticles comprising a taxane and an albumin, and b) instructions for administering the nanoparticle composition for treatment of bladder cancer.

35. The kit according to claim 34, wherein the kit comprises an effective amount of one other agent.

36. The kit according to claim 35, wherein the agent inhibits microtubule assembly.

37. The kit according to any one of claims 34-36, wherein the taxane is paclitaxel.

38. The kit according to any one of claims 34-37, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.

39. The kit according to any one of claims 34-38, wherein the taxane in the nanoparticles are coated with albumin.

40. The kit according to any one of claims 34-39, wherein the albumin is human albumin.

41. The kit according to any one of claims 34-39, wherein the albumin is human serum albumin.

42. A kit comprising: a) a composition comprising nanoparticles comprising a taxane and an albumin, b) a platinum-based agent, c) gemcitabine, and d) instructions for administering the nanoparticle composition, the platinum-based agent, and the gemcitabine for treatment of bladder cancer.

43. The kit according to claim 42, wherein the taxane is paclitaxel.

44. The kit according to claim 42 or 43, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.

45. The kit according to any one of claims 42-44, wherein the taxane in the nanoparticles are coated with albumin.

46. The kit according to any one of claims 42-45, wherein the albumin is human albumin.

47. The kit according to any one of claims 42-45, wherein the albumin is human serum albumin.